Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

FDA approves biosimilar competitor to Amgen’s Enbrel

By   /   Friday, April 26th, 2019  /   Comments Off on FDA approves biosimilar competitor to Amgen’s Enbrel

    Print       Email
The Food and Drug Administration has approved a second biosimilar competitor for Amgen’s blockbuster rheumatoid arthritis drug Enbrel. Korean biopharmaceutical company Samsung Bioepis’ biosimilar, called Eticovo, was approved to treat all the conditions treated by Enbrel. Amgen’s top-selling drug, Enbrel brought in just over $5 billion for the Thousand Oaks biotech giant in 2018, down…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email